Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 15;15(9):2090–2105. doi: 10.1080/21645515.2019.1581536

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — DENV-specific CD4⁺ T-cell responses in adults and/or adolescents in the US, Thailand and Puerto Rico. DENV-specific CD4⁺ T-cell responses after immunization with the F17 or F19 vaccines are presented for the overall sample subset of adults in the US and Thailand, and adolescents and adults in Puerto Rico (a), and for US subjects stratified by their DENV priming status at baseline, with numbers of evaluated subjects as indicated (b). Blood samples were obtained prior to each dose (Day [D] 0 and month [M] 6), 1 and 3 months after both the first dose (M1 and M3) and the second dose (M7 and M9). Data are presented in box-and-whiskers plots as percentages of DENV-specific CD4⁺ T cells expressing (after in vitro stimulation) at least two immune markers among IFN-γ, IL-2, TNF-α and CD40L of all CD4⁺ T cells, with medians, first and third quartiles, and minimum/maximum values presented.